BRIDGE-DS study: a multicenter, observational, retrospective analysis of dapagliflozin and sitagliptin combination on modifiable cardiovascular risk factors in T2DM patients with ASCVD or high cardiovascular risk
The dapagliflozin/sitagliptin FDC was effective and safe in managing patients with T2DM with cardiovascular risk factors and may offer cardioprotective benefits. Further investigations with longer follow-ups are necessary to confirm these findings.
Authors
- Anil Potdar
- Padoor Sethuraman Jagdish
- Ashutosh Kumar (ORCID: https://orcid.org/0000-0002-4949-1395)
- A. Tewari
- Naveen Bhamri
- Rohan Kesarkar
- Praveenkumar Devarbhavi (ORCID: https://orcid.org/0000-0003-0982-1369)
- Rajib Gayan
- Amit Asalkar
- Chandrakant Mishra
- Surendra Prasad
- Sachin Narendra Patil
- Ashish Prasad
- Sunil Bansal
- Abhijit Pednekar
- Manoj Chitale
- Chinnakonda R. Maheshbabu
- Devanand Samatbhai Rudach
Institutions
- Sarojini Naidu Medical College (IN)
- Max Super Speciality Hospital (IN)
- CARE Hospitals (IN)
- Sri Sri University (IN)
- Indian Institute of Information Technology Guwahati (IN)
- Diabetes Care and Research Foundation (IN)
- Shree Krishna Hospital (IN)
- Subbaiah Medical College (IN)
- Meenakshi Mission Hospital and Research Centre (IN)
- USV (India) (IN)
- BLK Super Speciality Hospital (IN)
- MemorialCare Health System (US)
- Bombay Hospital (IN)
- Dr. Mohan's Diabetes Specialities Centre (IN)
- MaxCure Hospitals (IN)
- National Law University Odisha (IN)
- M. P. Shah Medical College (IN)
Publication Details
- Journal
- Cardiovascular Endocrinology & Metabolism
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1097/xce.0000000000000330
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00